XSHE
300122
Market cap4.86bUSD
Oct 09, Last price
13.70CNY
1D
0.81%
1Q
12.57%
Jan 2017
-16.82%
IPO
-25.38%
Name
Chongqing Zhifei Biological Products Co Ltd
Chart & performance
P/E
—
P/S
3.66
EPS
—
Div yield, %
5.89%
Shrs. gr., 5y
8.39%
Rev. gr., 5y
-10.02%
Revenues
8.96b
-65.64%
Net income
-14.72b
L
CFO
5.17b
Dividend
Dec 25, 20240.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chongqing Zhifei Biological Products Co., Ltd. is a Chinese firm primarily engaged in the innovation, manufacturing, and commercialization of vaccines and other biological pharmaceuticals within the country. The company's establishment dates back to 2009, and its main operational base is located in Chongqing, China.
Key people
Lingfeng Jiang
President, Vice Chairman of the Board · since 2024
Zhenjing Li
Chief Financial Officer, Vice President, Director · since 2015
Jie Xun
General Manager-Risk Control Division
Wei Zhou
General Manager-Investment Department of Strategic Development Center · since 2024
Hong Fan
Vice President · since 2024
Xisheng Jiang
Vice President · since 2012
Danqing Leng
Vice President · since 2024
Fei Qin
Vice President, Secretary of the Board, Director · since 2016
Jie Shao
Vice President · since 2024
Haitian Sun
Vice President · since 2016
Jiaji Wang
Vice President · since 2024
Li Xie
Vice President · since 2016
Haiping Xu
Vice President · since 2024
Wenqiao Yao
Vice President · since 2024
Yu Zhang
Vice President · since 2024
Jing Zhang
Vice President · since 2016
Ke Yuan
Deputy General Manager-Clinical Research Management Center · since 2024
Zhijun Wang
Chief Engineer · since 2019
Lin Du
Director · since 2017
Rensheng Jiang
Chairman of the Board · since 2024
Headquarters & legal address
重庆市江北区金源路7号25-1至25-8
江北区, CQ 100000
CN
江北区, CQ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||